Abstract
No public abstract is available from the verified source records.
Guoyu Lan
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy
2026 · 0 citations
Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change
2026 · 0 citations
Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders
2026 · 0 citations
No local citing links have been materialized yet.
Lecanemab in early Alzheimer's disease
10.1056/nejmoa2212948 · 2023
Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial
10.1001/jama.2023.13239 · 2023
New landscape of the diagnosis of Alzheimer's disease
10.1016/s0140-6736(25)01294-2 · 2025
Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders
10.1016/s1474-4422(26)00246-2 · 2026
Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy
10.1016/s1474-4422(26)00285-1 · 2026
Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change
10.1016/s1474-4422(26)00248-6 · 2026
Comprehensive evaluation of plasma tau biomarkers for detecting and monitoring Alzheimer's disease in a multicenter and multiethnic aging population
10.1038/s43587-025-00904-3 · 2025
Prognostic value of blood-based p-tau217 levels for progression to cognitive impairment
10.1001/jama.2026.12556 · 2026
Amyloid PET quantitation and centiloid thresholds in the diagnosis of Alzheimer disease: an individual participant data meta-analysis
10.1001/jama.2026.13116 · 2026
No additional external references are available.